Nurix Therapeutics’ $209 Million Initial Public Offering


Fenwick & West represented Nurix Therapeutics in the offering.

Nurix Therapeutics, Inc. (NASDAQ: NRIX), a company developing targeted protein modulation drugs, executed its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, were $209 million.

J.P. Morgan, Piper Sandler and Stifel acted as joint bookrunning managers for the proposed offering. Needham & Company acted as lead manager.

The Fenwick transaction team representing Nurix Therapeutics included corporate partners Michael Brown (Picture), Amanda Rose and Robert Freedman, and associates Jennifer Hitchcock, Katherine Duncan, Annie Omata and Alyssa Zhang; as well as executive compensation & employee benefits partner Elizabeth Gartland and associate Corinne Nhaissi.

Involved fees earner: Michael Brown – Fenwick & West LLP; Katherine Duncan – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Elizabeth Gartland – Fenwick & West LLP; Jennifer Hitchcock – Fenwick & West LLP; Corinne Nhaissi – Fenwick & West LLP; Annie Omata – Fenwick & West LLP; Amanda Rose – Fenwick & West LLP; Alyssa Zhang – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Nurix, Inc. ;

Author: Ambrogio Visconti